메뉴 건너뛰기
Neurology
Volumn 64, Issue 5, 2005, Pages 778-779
Coming of age: The use of immunomodulatory therapy in children with multiple sclerosis
Author keywords

[No Author keywords available]
Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER;
EID: 14644425214     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000153532.80277.21     Document Type: Editorial
Times cited : (9)
References (10)
  • 1
    • 85056689201 scopus 로고    scopus 로고
    • Clinical features
    • Cook SD, ed. New York: Marcel Dekker
    • Miller AE. Clinical features. In: Cook SD, ed. Handbook of multiple sclerosis. New York: Marcel Dekker, 2001;231-232.
    • (2001) Handbook of Multiple Sclerosis , pp. 231-232
    • Miller, A.E.1
  • 2
  • 3
    • 0037154192 scopus 로고    scopus 로고
    • Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
    • Goodin DS, Frohman EM, Garmany GP, Jr., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
    • (2002) Neurology , vol.58 , pp. 169-178
    • Goodin, D.S.1    Frohman, E.M.2    Garmany Jr., G.P.3
  • 4
    • 0037168760 scopus 로고    scopus 로고
    • Course and prognosis in early-onset MS: Comparison with adult-onset forms
    • Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002;59:1922-1928.
    • (2002) Neurology , vol.59 , pp. 1922-1928
    • Simone, I.L.1    Carrara, D.2    Tortorella, C.3
  • 5
    • 14644440773 scopus 로고    scopus 로고
    • Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a
    • Pohl D, Rostasy K, Gärtner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology 2005;64:888-890.
    • (2005) Neurology , vol.64 , pp. 888-890
    • Pohl, D.1    Rostasy, K.2    Gärtner, J.3    Hanefeld, F.4
  • 6
    • 0001971227 scopus 로고
    • Post-marketing surveillance - How many patients?
    • Lewis JA. Post-marketing surveillance - how many patients? Trends Pharmacol Sci 1981;2:93-94.
    • (1981) Trends Pharmacol Sci , vol.2 , pp. 93-94
    • Lewis, J.A.1
  • 7
    • 0034820525 scopus 로고    scopus 로고
    • Interferon beta-1α in children with multiple sclerosis is well tolerated
    • Waubant E, Hietpas J, Stewart T, et al. Interferon beta-1α in children with multiple sclerosis is well tolerated. Neuropediatrics 2001;32:211-213.
    • (2001) Neuropediatrics , vol.32 , pp. 211-213
    • Waubant, E.1    Hietpas, J.2    Stewart, T.3
  • 8
    • 0034834942 scopus 로고    scopus 로고
    • Interferon-beta treatment in patients with childhood-onset multiple sclerosis
    • Mikaeloff Y, Moreau T, Debouverie M, et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr 2001;139:443-446.
    • (2001) J Pediatr , vol.139 , pp. 443-446
    • Mikaeloff, Y.1    Moreau, T.2    Debouverie, M.3
  • 9
    • 0032991525 scopus 로고    scopus 로고
    • Interferon beta-1b and childhood multiple sclerosis
    • Adams AB, Tyor WR, Holden KR. Interferon beta-1b and childhood multiple sclerosis. Pediatr Neurol 1999;21:481-483.
    • (1999) Pediatr Neurol , vol.21 , pp. 481-483
    • Adams, A.B.1    Tyor, W.R.2    Holden, K.R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.